MX2024013120A - Analisis del transcriptoma para el tratamiento de la inflamacion - Google Patents
Analisis del transcriptoma para el tratamiento de la inflamacionInfo
- Publication number
- MX2024013120A MX2024013120A MX2024013120A MX2024013120A MX2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A
- Authority
- MX
- Mexico
- Prior art keywords
- treating inflammation
- transcriptome analysis
- disease
- dupilumab
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
- C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263334837P | 2022-04-26 | 2022-04-26 | |
| PCT/US2023/066197 WO2023212569A1 (en) | 2022-04-26 | 2023-04-25 | Transcriptome analysis for treating inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013120A true MX2024013120A (es) | 2024-12-06 |
Family
ID=86469406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013120A MX2024013120A (es) | 2022-04-26 | 2024-10-24 | Analisis del transcriptoma para el tratamiento de la inflamacion |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230340601A1 (https=) |
| EP (1) | EP4514995A1 (https=) |
| JP (1) | JP2025515307A (https=) |
| CN (1) | CN119137282A (https=) |
| AU (1) | AU2023259352A1 (https=) |
| CA (1) | CA3246860A1 (https=) |
| MX (1) | MX2024013120A (https=) |
| WO (1) | WO2023212569A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117949666B (zh) * | 2024-01-12 | 2025-07-15 | 首都医科大学附属北京同仁医院 | 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用 |
| WO2025244092A1 (ja) * | 2024-05-23 | 2025-11-27 | 国立研究開発法人理化学研究所 | アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット |
| WO2025244094A1 (ja) * | 2024-05-23 | 2025-11-27 | 国立研究開発法人理化学研究所 | アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット |
| CN119932179B (zh) * | 2025-04-08 | 2025-06-27 | 杭州易文赛生物技术有限公司 | 用于评价间充质干细胞治疗炎症性肠炎效果的标志物组合物及其应用 |
| CN120510912A (zh) * | 2025-05-20 | 2025-08-19 | 北京大学人民医院 | 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质 |
| CN121109581B (zh) * | 2025-11-17 | 2026-03-06 | 杭州易文赛生物技术有限公司 | 用于评价间充质干细胞治疗特应性皮炎效果的标志物组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR098155A1 (es) * | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| WO2019217478A1 (en) * | 2018-05-09 | 2019-11-14 | Dermtech, Inc. | Novel gene classifiers and uses thereof in autoimmune diseases |
| EP4153300A1 (en) * | 2020-05-22 | 2023-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
-
2023
- 2023-04-25 CA CA3246860A patent/CA3246860A1/en active Pending
- 2023-04-25 CN CN202380035733.6A patent/CN119137282A/zh active Pending
- 2023-04-25 EP EP23725544.3A patent/EP4514995A1/en active Pending
- 2023-04-25 JP JP2024562852A patent/JP2025515307A/ja active Pending
- 2023-04-25 AU AU2023259352A patent/AU2023259352A1/en active Pending
- 2023-04-25 US US18/306,737 patent/US20230340601A1/en active Pending
- 2023-04-25 WO PCT/US2023/066197 patent/WO2023212569A1/en not_active Ceased
-
2024
- 2024-10-24 MX MX2024013120A patent/MX2024013120A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230340601A1 (en) | 2023-10-26 |
| WO2023212569A1 (en) | 2023-11-02 |
| EP4514995A1 (en) | 2025-03-05 |
| AU2023259352A1 (en) | 2024-10-10 |
| CN119137282A (zh) | 2024-12-13 |
| CA3246860A1 (en) | 2023-11-02 |
| JP2025515307A (ja) | 2025-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013120A (es) | Analisis del transcriptoma para el tratamiento de la inflamacion | |
| AU2019262220A8 (en) | Methods of diagnosing and treating based on site-specific tau phosphorylation | |
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| PH12022550578A1 (en) | Method for identifying responders to smarca2/4 degraders | |
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| MX2023007587A (es) | Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb). | |
| WO2020154268A3 (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors | |
| EA036698B9 (ru) | Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| MX2024007806A (es) | Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos. | |
| WO2019236750A3 (en) | Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders | |
| MX2021009247A (es) | Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1. | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| MX2023006598A (es) | Biomarcadores agonistas del trem2 y métodos para usarlos. | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| WO2018064013A8 (en) | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| ATE531813T1 (de) | System zur überwachung einer bakteriellen tumorbehandlung | |
| WO2019168478A8 (en) | A method of determining a risk of cancer | |
| WO2006025028A3 (en) | Novel classification method of blood cells and tailor-made therapy and prevention based thereupon | |
| WO2003030725A3 (en) | Pancreatic cancer diagnosis and therapies | |
| MX2018011679A (es) | Biomarcadores de proteopatias y usos de los mismos. | |
| EP4327818A3 (en) | Improved anti-senescence compounds and uses for the treatment of cancer | |
| EA202092540A1 (ru) | Комбинации для лечения рака |